Ottobock stock tracks Blue Arbor's RESTORE development push

Ottobock is deepening its exposure to advanced prosthetic control after Blue Arbor Technologies announced on Wednesday, October 28, 2026, that it had closed a 10.5 million US-dollar Series A financing led by Ottobock. The announcement was published by Blue Arbor Technologies.

The proceeds will fund the completion of feasibility testing, preparations for a US Food and Drug Administration Investigational Device Exemption and US clinical studies for RESTORE's External Sensing Unit. Blue Arbor also plans to begin developing a fully implantable Internal Sensing Unit.

Clinical path remains central

RESTORE is designed to connect a patient's peripheral nervous system with a robotic prosthetic limb. The system aims to enable independent and simultaneous control of the fingers, wrist and elbow, potentially improving dexterity and reliability for people with limb loss.

Blue Arbor said two human implantations had been completed. Feasibility work includes a successful second-in-human procedure using the External Sensing Unit at the Medical University of Vienna. The technology was also selected for a University of Michigan clinical study supported by a UG3 grant from the National Institutes of Health, which will compare surface electrodes with implanted electrodes for prosthetic control.

RESTORE has received FDA Breakthrough Device Designation and has been accepted into the FDA's Total Product Life Cycle Advisory Program Pilot. Those milestones support the development and regulatory path, but they do not amount to commercial approval. Blue Arbor states that RESTORE remains an investigational device.

Strategic exposure without near-term sales

For Ottobock, the transaction extends its technology pipeline beyond established prosthetic, neuro-orthotic and wearable bionic products. The financial significance currently rests on future product capability, clinical evidence and regulatory progress rather than an immediate contribution to revenue.

The real-time quote of Ottobock stock was 49.00 euros on Lang & Schwarz at 12:36:43 CET on Thursday, November 5, 2026.

The broader German market is covered in current DAX market reports.

More news and analyses on Ottobock stock will track clinical evidence, regulatory milestones and the company's broader technology strategy.